CTRI/2021/03/032072
Completed
Phase 3
A Prospective, Single center, single arm study to Evaluate Efficacy and safety of Ayurvedic Kadha in health and immunity related parameters in mild COVID-19 patients. - Kadha
MARC Laboratories Ltd0 sites50 target enrollmentTBD
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Sponsor
- MARC Laboratories Ltd
- Enrollment
- 50
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Age \> 18 years
- •2\. Written Informed consent is documented
- •3\. COVID\-19 positive clinical symptoms and (subsequently) confirmed by the current recommended confirmatory test (RT PCR).
- •4\. Can take oral medicines.
- •5\. Mild\-moderate grade of the disease.
Exclusion Criteria
- •1\. Known sensitivity to any of the ingredients
- •2\. Bleeding haemorrhoids
- •3\. Serious stages of the illnesses
- •4\. ICU admitted patients
- •5\. Pre\-existing GI symptoms like nausea or vomiting
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 4
Clinical study to asses the CT angiography results following the use of the MeRes100 Sirolimus-Eluting Bioresorbable Vascular Scaffold System in patients with coronary artery disease.Health Condition 1: I251- Atherosclerotic heart disease of native coronary arteryCTRI/2024/04/066128Dr Keyur Parikh
Active, not recruiting
Phase 3
Efficacy and safety of Sirolimus granules twice daily administration in patients with intractuable vascular malformationsIntractable vascular malformationsVascular disordersD054079JPRN-jRCTs031200055Mochizuki Shinji11
Recruiting
Phase 2
Study for assessing the effect of blood level guided adjustment of posconazole doses (an oral drug to prevent fungal infections) in preventing fungal infections in blood cancer patientsHealth Condition 1: null- Acute Myeloid Leukemia patients started on remission induction chemotherapyCTRI/2017/06/008810Tata Memorial Hospital90
Withdrawn
Phase 3
A Prospective, Multi-Center, Single Arm Study of the Conor Cobalt Chromium Reservoir Based Stent (Nevo) with Sirolimus Elution in Native Coronary Artery Lesions (CP-07 protocol)NL-OMON32462Conor Medsystems, LLC (maakt deel uit van Johnson & Johnson); contact persoon Emily Hergenreter40
Completed
Not Applicable
OFT-G1-301 StudyCongenital heart diseaseJPRN-jRCT1080224691TEIJIN LIMITED / TEIJIN PHARMA LIMITED30